Top

CardioVascular and Interventional Radiology

Published in:

Open Access 01-10-2018 | Clinical Investigation

Patient-Reported Outcomes of Bleomycin Sclerotherapy for Low-Flow Vascular Malformations and Predictors of Improvement

Authors: S. E. R. Horbach, J. S. van de Ven, P. T. Nieuwkerk, Ph. I. Spuls, C. M. A. M. van der Horst, J. A. Reekers

Published in: CardioVascular and Interventional Radiology | Issue 10/2018

Abstract

Purpose

There is paucity of data on patient-perceived outcomes of bleomycin sclerotherapy for low-flow vascular malformations. In this study, the long-term outcomes of bleomycin sclerotherapy were investigated in terms of quality of life (QoL) and patient-perceived changes in health.

Materials and Methods

A cohort of Dutch patients with vascular malformations treated with bleomycin sclerotherapy (June 2010-November 2015) completed a questionnaire evaluating disease symptoms, QoL (Short Form 36), patient-perceived change in health status (Global Rating of Change scales) and treatment satisfaction. QoL was assessed for the patient’s status before and after treatment and was analyzed relative to an age and sex-matched Dutch reference population. Predictive factors associated with QoL and patient-perceived improvement in overall health status were assessed using multivariable linear and logistic regression analyses, respectively.

Results

Seventy-seven patients, with a median follow-up of 22 months, were enrolled. About half of the respondents (49.3%) indicated that they perceived (any form of) improvement in their overall health status. Most often improved were the specific health aspects ‘pain’ (54.5%) and ‘overall severity of symptoms’ (57.1%). No factors were significantly predictive for patient-perceived improvement in health with respect to the vascular malformation. Impairment in work- or study-related activities prior to sclerotherapy was found to negatively impact physical QoL at follow-up (p = 0.03).

Conclusion

Approximately half of patients with low-flow vascular malformations indicate an improvement in overall health status following bleomycin sclerotherapy, particularly concerning pain and severity of symptoms. However, most patients only perceived little to moderate improvement to their health and desire further treatment.

Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies. Pediatrics. 2015;136(1):e203–14. https://doi.org/10.1542/peds.2014-3673.CrossRefPubMed

Dasgupta R, Fishman SJ. ISSVA classification. Semin Pediatr Surg. 2014;23(4):158–61. https://doi.org/10.1053/j.sempedsurg.2014.06.016.CrossRefPubMed

Breugem CC, Merkus MP, Smitt JH, Legemate DA, van der Horst CM. Quality of life in patients with vascular malformations of the lower extremity. Br J Plast Surg. 2004;57(8):754–63. https://doi.org/10.1016/j.bjps.2004.05.006.CrossRefPubMed

Fahrni JO, Cho EY, Engelberger RP, Baumgartner I, von Kanel R. Quality of life in patients with congenital vascular malformations. Journal of Vascular Surgery Venous and Lymphatic Disorders. 2014;2(1):46–51. https://doi.org/10.1016/j.jvsv.2013.09.001.CrossRefPubMed

Zhang W, Chen G, Ren JG, Zhao YF. Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations. Br J Pharmacol. 2013;170(6):1210–20. https://doi.org/10.1111/bph.12355.CrossRefPubMedPubMedCentral

Narkio-Makela M, Makela T, Saarinen P, Salminen P, Julkunen I, Pitkaranta A. Treatment of lymphatic malformations of head and neck with OK-432 sclerotherapy induce systemic inflammatory response. Eur Arch Otorhinolaryngol. 2011;268(1):123–9. https://doi.org/10.1007/s00405-010-1332-x.CrossRefPubMed

Zhao JH, Zhao YF, Chen XM, Zheng X, Zhang WF. Histological investigation of veins and venous malformations after injection of sclerosing agents. Asian Journal of Oral and Maxillofacial Surgery. 2002;14(4):226–31.CrossRef

Horbach SE, Lokhorst MM, Saeed P, de Gouyon Matignon de Pontouraude CM, Rothova A, van der Horst CM. Sclerotherapy for low-flow vascular malformations of the head and neck: A systematic review of sclerosing agents. JPRAS. 2015. https://doi.org/10.1016/j.bjps.2015.10.045.

Steiner F, FitzJohn T, Tan ST. Ethanol sclerotherapy for venous malformation. ANZ J Surg. 2014. https://doi.org/10.1111/ans.12833.PubMedCrossRef

10.

Wiegand S, Eivazi B, Zimmermann AP, Sesterhenn AM, Werner JA. Sclerotherapy of lymphangiomas of the head and neck. Head Neck. 2011;33(11):1649–55. https://doi.org/10.1002/hed.21552.CrossRefPubMed

11.

Churchill P, Otal D, Pemberton J, Ali A, Flageole H, Walton JM. Sclerotherapy for lymphatic malformations in children: a scoping review. J Pediatr Surg. 2011;46(5):912–22. https://doi.org/10.1016/j.jpedsurg.2011.02.027.CrossRefPubMed

12.

Horbach SE, Rigter IM, Smitt JH, Reekers JA, Spuls PI, van der Horst CM. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. Plast Reconstr Surg. 2016;137(1):244–56. https://doi.org/10.1097/prs.0000000000001924.CrossRefPubMed

13.

Blaise S, Charavin-Cocuzza M, Riom H, Brix M, Seinturier C, Diamand JM, et al. Treatment of low-flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review. Eur J Vasc Endovasc Surg. 2011;41(3):412–7. https://doi.org/10.1016/j.ejvs.2010.10.009.CrossRefPubMed

14.

Gurgacz S, Zamora L, Scott NA. Percutaneous sclerotherapy for vascular malformations: a systematic review. Ann Vasc Surg. 2014;28(5):1335–49. https://doi.org/10.1016/j.avsg.2014.01.008.CrossRefPubMed

15.

Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int. 2004;19(12):766–73. https://doi.org/10.1007/s00383-003-1058-6.CrossRefPubMed

16.

Froudarakis M, Hatzimichael E, Kyriazopoulou L, Lagos K, Pappas P, Tzakos AG, et al. Revisiting bleomycin from pathophysiology to safe clinical use. Critical Reviews in Oncology/Hematology. 2013;87(1):90–100. https://doi.org/10.1016/j.critrevonc.2012.12.003.CrossRefPubMed

17.

Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot. 1966;19(5):200–9.PubMed

18.

Sikic BI. Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv. 1986;5(1):81–91.PubMed

19.

Love Z, Hsu DP. Low-flow vascular malformations of the head and neck: clinicopathology and image guided therapy. J Neurointerv Surg. 2012;4(6):414–25. https://doi.org/10.1136/neurintsurg-2011-010126.CrossRefPubMed

20.

Choi DJ, Alomari AI, Chaudry G, Orbach DB. Neurointerventional management of low-flow vascular malformations of the head and neck. Neuroimaging Clin N Am. 2009;19(2):199–218. https://doi.org/10.1016/j.nic.2009.01.003.CrossRefPubMed

21.

Spence J, Krings T, TerBrugge KG, Agid R. Percutaneous treatment of facial venous malformations: a matched comparison of alcohol and bleomycin sclerotherapy. Head Neck. 2011;33(1):125–30. https://doi.org/10.1002/hed.21410.CrossRefPubMed

22.

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMed

23.

Coombes BK, Bisset L, Brooks P, Khan A, Vicenzino B. Effect of corticosteroid injection, physiotherapy, or both on clinical outcomes in patients with unilateral lateral epicondylalgia: a randomized controlled trial. JAMA. 2013;309(5):461–9. https://doi.org/10.1001/jama.2013.129.CrossRefPubMed

24.

Hancock MJ, Maher CG, Latimer J, McLachlan AJ, Cooper CW, Day RO, et al. Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. Lancet. 2007;370(9599):1638–43. https://doi.org/10.1016/s0140-6736(07)61686-9.CrossRefPubMed

25.

Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163–70. https://doi.org/10.1179/jmt.2009.17.3.163.CrossRefPubMedPubMedCentral

26.

Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998;51(11):1055–68.CrossRefPubMed

27.

Blome C, Augustin M. Measuring change in quality of life: bias in prospective and retrospective evaluation. Value Health. 2015;18(1):110–5. https://doi.org/10.1016/j.jval.2014.10.007.CrossRefPubMed

28.

Oduber CE, Khemlani K, Sillevis Smitt JH, Hennekam RC, van der Horst CM. Baseline Quality of Life in patients with Klippel-Trenaunay syndrome. JPRAS. 2010;63(4):603–9. https://doi.org/10.1016/j.bjps.2009.01.055.PubMedCrossRef

29.

Ono Y, Osuga K, Takura T, Nakamura M, Shibamoto K, Yamamoto A, et al. Cost-effectiveness analysis of percutaneous sclerotherapy for venous malformations. JVIR. 2016;27(6):831–7. https://doi.org/10.1016/j.jvir.2015.12.019.CrossRefPubMed

Title: Patient-Reported Outcomes of Bleomycin Sclerotherapy for Low-Flow Vascular Malformations and Predictors of Improvement
Authors: S. E. R. Horbach
J. S. van de Ven
P. T. Nieuwkerk
Ph. I. Spuls
C. M. A. M. van der Horst
J. A. Reekers
Publication date: 01-10-2018
Publisher: Springer US
Published in: CardioVascular and Interventional Radiology / Issue 10/2018
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-018-1999-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Patient-Reported Outcomes of Bleomycin Sclerotherapy for Low-Flow Vascular Malformations and Predictors of Improvement

Abstract

Purpose

Materials and Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Materials and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2018

Stent Fracture After Transjugular Intrahepatic Portosystemic Shunt: Reply

Could Monopolar Mode be a Suitable Strategy of Energy Deposition for Performing No-Touch Radiofrequency Ablation of Liver Tumor ≤ 5 cm?

Infectious Outcomes from Renal Tumor Ablation: Prophylactic Antibiotics or Not?

New Implant-Based Technologies in the Spine

Assessment of Therapy Response to Transarterial Radioembolization for Liver Metastases by Means of Post-treatment MRI-Based Texture Analysis

A Prospective Clinical Study of a Percutaneous Vascular Access System for Hemodialysis Catheters